Key points are not available for this paper at this time.
is a promising biomarker for monitoring the response to therapy for children with RO+ MS LCH or RO- LCH resistant to first-line chemotherapy.
Share your take
Add a clinician perspective alongside expert commentary.
Heritier et al. (Tue,) studied this question.